- Current report filing (8-K)
July 13 2009 - 3:39PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported):
July 6, 2009
AXM
PHARMA, INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
001-31886
|
|
20-0745214
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
20955
Pathfinder Road, Suite 100
Diamond
Bar, CA 91765
|
|
10011
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant’s
telephone number, including area code:
(646)
393-4365
|
|
|
|
|
|
|
|
N/A
|
(Former
name or former address, if changed since last
report.)
|
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General Instruction
A.2. below):
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers
|
(b) Resignation
of Director
On July
6, 2009,
Mr. Baozhong Zhang
resigned from his position as a director of AXM Pharma, Inc. (the
“Company”). Mr.
Zhang advised the
Company that he was resigning for personal reasons. He
did not
note any disagreement with the Company concerning any matter relating to the
Company's operations, policies or practices as a reason for his
resignation.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
AXM
PHARMA,INC.
|
|
|
|
July
13, 2009
|
|
/s/ Wei Shi
Wang
|
|
|
Wei Shi Wang
|
|
|
Chief Executive Officer
|
AXM Pharma (CE) (USOTC:AXMP)
Historical Stock Chart
From Sep 2024 to Oct 2024
AXM Pharma (CE) (USOTC:AXMP)
Historical Stock Chart
From Oct 2023 to Oct 2024